Evidence map›Paper›PMID 31022866›Full record

ReviewInternational journal of molecular sciences2019

The Role of the Immune System in Cutaneous Squamous Cell Carcinoma.

Matthew J Bottomley, Jason Thomson, Catherine Harwood, Irene Leigh

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05246228 (Immune System Modulation and Outcome in High-risk Cutaneous Squamous Cell Carcinoma Treated With Surgery and Radiotherapy), which is not on this map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05246228 unknown statusnot on this mapstarted 2022, after this paper: background citation

Immune System Modulation and Outcome in High-risk Cutaneous Squamous Cell Carcinoma Treated With Surgery and Radiotherapy: a Prospective Study

TypeobservationalSponsorAzienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaRan2022 to 2025Enrolled42ConditionsSquamous Cell Carcinoma of the SkinArmsPeripheral blood sampling in order to evaluate changes in the circulating immune population
3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 111 citations in OpenAlex.

  1. Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  2. The tumor microenvironment of cutaneous squamous cell carcinoma in high-risk patient groups: A scoping review.JID innovations : skin science from molecules to population health · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew J BottomleyTransplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK. matthew.bottomley@nds.ox.ac.uk.ORCID 0000-0001-5793-4777
Jason ThomsonCentre for Cell Biology and Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK. jason.thomson@doctors.net.uk.ORCID 0000-0002-6644-0979
Catherine HarwoodCentre for Cell Biology and Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK. caharwood@doctors.org.uk.
Irene LeighCentre for Cell Biology and Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK. i.m.leigh@qmul.ac.uk.
Queen Mary University of London · GBUniversity of Oxford · GB

Funding

Medical Research Council MR/T001720/1
6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. In immunosuppressed populations it is a source of considerable morbidity and mortality due to its enhanced recurrence and metastatic potential. In common with many malignancies, leucocyte populations are both protective against cancer development and also play a role in 'sculpting' the nascent tumor, leading to loss of immunogenicity and tumor progression. UV radiation and chronic viral carriage may represent unique risk factors for cSCC development, and the immune system plays a key role in modulating the response to both. In this review, we discuss the lessons learned from animal and ex vivo human studies of the role of individual leucocyte subpopulations in the development of cutaneous SCC. We then discuss the insights into cSCC immunity gleaned from studies in humans, particularly in populations receiving pharmacological immunosuppression such as transplant recipients. Similar insights in other malignancies have led to exciting and novel immune therapies, which are beginning to emerge into the cSCC clinical arena.

Indexed as

Adaptive ImmunityImmunity, InnateAnimalsCarcinoma, Squamous CellHumansImmunotherapySkinSkin NeoplasmscancercSCCcutaneousimmunityimmunologyleucocytemalignancySCCskinsquamous cell carcinoma

Identifiers

PMID31022866
PMCPMC6515307
OpenAlexW2942128564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.